Anthem Biosciences (ANTHEM) — Announcement

📢 Key Event
Anthem Biosciences reported Q1 FY27 results with 39.6% EBITDA margin and Rs 1,720 crore cash position.

🔄 What Changed
60% order book visibility secured, Unit 4 capex planned at Rs 1,200 crores

🔮 What's Next
Unit 4 commissioning by end of next year; tax rate normalization to 25-25.5%; ESOP cost to decline to Rs 5 crores in FY28

💡 Investor Takeaway
Shareholders should note that order book visibility and capacity expansion support long-term growth despite near-term margin pressure.

⚠️ Risks
None explicitly flagged

Anthem Biosciences reported Q1 FY27 results showing consolidated revenue of Rs 418 crores, with CRDMO contributing 81.5% and specialty ingredients 18.5%, EBITDA margin at 39.6%, and PAT margin at 27.1%, supported by a strong cash position of Rs 1,720 crores and 60% order book visibility. Management highlighted capacity expansion plans including commissioning of Unit 4 by end of next year, new customer acquisition via a Big Pharma portfolio purchase, and pipeline progress with 10 late-phase ADC/GLP projects targeting commercialization within 18-24 months. Despite a 25% YoY revenue decline in Q1, full-year growth remains on track with historical double-digit rates, and margin sustainability is expected through technology innovation and customer value drivers like reliability and regulatory compliance.

📄 View Original Announcement (PDF)

📊 Stock Analysis — ANTHEM ✨ Ask AI About This

About Anthem Biosciences Limited (ANTHEM)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹53,084.93 Cr P/E: 91.9 ROE: 18.9% ROCE: 25.5% Div Yield: 0.21%

View full ANTHEM stock details →

📡 Get AI alerts when ANTHEM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ANTHEM — Free

💡 Ask AI about this filing

"How will Unit 4 capex impact FY28 margins?" "What is the expected revenue contribution from the Big Pharma acquisition?" "When will late-phase pipeline projects begin generating commercial revenue?"

Ask AI Free →

📊 More ANTHEM filings

See all ANTHEM filings →

🔥 Also filed on 27 July 2026

FAIRCHEMOR Fairchem Organics Limited Financial Results MPHASIS MphasiS Limited Insider Trading NTPC NTPC Limited Corporate Action CCL CCL Products (India) Limited Corporate Action ITI ITI Limited Announcement SHRIRAMFIN Shriram Finance Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ANTHEM files new disclosures

Track ANTHEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ANTHEM — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd